A childhood asthma death in a clinical trial: potential indicators of risk.
A 9 yr old girl with a history of eczema and asthma was admitted to our specialist asthma service and recruited into a trial designed to investigate systemic as well as therapeutic benefits of inhaled corticosteroids. Eight months after referral the patient died from an acute asthma attack. This childhood asthma death during an inhaled steroid trial has facilitated identification of risk factors. Despite good clinical response to inhaled corticosteroids, the patient was distinguishable from the other patients by: increased variability of the morning and evening peak flow rates; increased reactivity, though not sensitivity, to histamine; and an unprecedented rise in serum soluble interleukin-2 receptor levels immediately after commencing inhaled steroids. The immunological basis for corticosteroid resistance and immunohistochemical studies on postmortem specimens from asthma deaths suggest that T-cell activation markers may be indicators of the fatality prone asthmatic.
Warner
J O
JO
Child Health, University of Southampton, Southampton General Hospital, UK.
Nikolaizik
W H
WH
Besley
C R
CR
Warner
J A
JA
D000280:Administration, Inhalation; D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage* / Q000627:therapeutic use; D001249:Asthma / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use; D019819:Budesonide / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D002940:Circadian Rhythm / Q000502:physiology; D002986:Clinical Trials as Topic; D004351:Drug Resistance; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008297:Male; D012123:Pulmonary Ventilation / Q000502:physiology; D015375:Receptors, Interleukin-2 / Q000097:blood; D012307:Risk Factors
D000305:Adrenal Cortex Hormones; D001993:Bronchodilator Agents; D015375:Receptors, Interleukin-2; D019819:Budesonide